Arthneeti
Medplus Health Services LtdQ1 FY24

Medplus Health Services Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹656P/E: 37.7Market Cap: ₹7.9K CrSector: Retailing

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • MedPlus has rapidly expanded its membership base to 110,000 within 18 months, aiming to reach 250,000 to 500,000 subscribers as brand awareness grows (Page 17).
  • The new branded private label initiative, launched mid-June, has driven strong top-line growth and is currently about 14% of sales in Hyderabad and Telangana, expected to increase above 20% with SKU expansion to 750–800 (Pages 13-14).
  • Revenue per store in Tier-2 and Tier-3 cities may be slightly lower than metros but with better profitability due to product mix and lower costs, supporting expansion in smaller towns (Pages 15-16).
  • Store count growing steadily; 995 net stores added in past 12 months, with 44% in Tier-2+ cities, focusing on balanced growth and profitability (Pages 3-4).
  • Overall revenue growth guidance remains 25% to 30%, with the new business ventures and private label expansion contributing but not warranting guidance change yet (Page 14).

See what Medplus Health Services Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • As of the August 08, 2023 call, MedPlus Health Services Limited reported a net debt position of zero for the quarter, indicating no current debt burden.
  • The management expressed a cautious approach toward expansion, focusing on ensuring sufficient accrual and minimizing borrowing.
  • There was no indication or announcement during the call regarding any imminent or planned fundraising through debt or equity.
  • The company emphasized organic growth funded through cash accrual rather than external borrowing.
  • Any future need for fundraising will be communicated as the company progresses, but currently, there is no stated plan for new debt or equity raising.

See what Medplus Health Services Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes
- The company is focusing on expanding its private label pharma range from 433 SKUs to around 750-800 SKUs within the next three months, indicating investment in product development and manufacturing capacity. - They are expanding store network into Tier-2 and Tier-3 cities with over 44% of stores currently in these locations, which implies ongoing capital expenditure on new store openings. - Plans to add 800 to 1,000 new stores in the current year, reflecting continued capital investment in retail infrastructure. - Development of central warehouses and supply chain infrastructure in new cities, particularly in smaller towns, to support new store additions. - Expansion of diagnostic business with new centers launched and plans for growth in Hyderabad. - No explicit mention of large one-time strategic investments or capex outside these growth and expansion initiatives, but the scale-up implies continuous capital deployment. Net debt is zero as of the latest quarter, indicating internally funded growth.

Track Medplus Health Services Ltd — get its next earnings analysis in your feed

Margin guidance

Category 2
  • MedPlus expects top-line growth of around 25% to 30% YoY, with no immediate change to this guidance despite new business ventures (Page 14).
  • The diagnostic business is expanding, currently operating at a loss but with growing revenue and membership, indicating future profitability potential (Page 5, 17).
  • Gross margin experienced a seasonal dip due to extra discounts and inventory write-downs, but margin improvement is expected as private label sales increase (Page 17).
  • EBITDA margin at mature stores (>2 years) stands around 9.7%; store-level EBITDA improves as stores mature over 2+ years (Page 5).
  • Scale benefits and private label expansion (currently 14.5% of sales, targeted to increase) are expected to drive margin expansion and EBITDA growth (Pages 9, 13-14).
  • Corporate expenses are currently ~2%, warehousing ~3% of sales; overall EBITDA margin for a two-year-old network approximates 5%, expected to improve with scale and private label growth (Page 10).
  • Net debt is zero, supporting financial health for profitable growth (Page 10).

Order book

The provided transcript from MedPlus Health Services Limited's Q1 FY '24 earnings call does not mention any information related to current or expected order book or pending orders. The discussion primarily focuses on: - Store counts and expansions - Subscription and diagnostic business performance - Private label product range and margins - Revenue, EBITDA, and inventory metrics - Renewal rates in diagnostic subscriptions - Competition and discounting strategies No details on order book or pending orders were disclosed or discussed on page 17 or surrounding pages.

How does Medplus Health Services Ltd rank vs peers in Retailing?

Pro feature
ThisMedplus Health Services Ltd
Rev 2Mar 2
See where Medplus Health Services Ltd sits in RetailingSee which companies these are, and every other name in the sector.Open rankings

How does Medplus Health Services Ltd rank in Retailing?

Compare Medplus Health Services Ltd against every Retailing company (Q1 FY24) on revenue, margins and earnings-call signals.

View Retailing leaderboard →

Continue your research

What Medplus Health Services Ltd's management said in earlier quarters

Others in Retailing this season

  • Patel Retail Ltd (Q1 FY27)

    INR 1 crore monthly revenue. Key concall takeaways from Patel Retail Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Credo Brands Marketing Ltd (Q1 FY27)

    Profit after tax for Q1 FY27 was modest (INR 2.3 crores with 1.8% PAT margin), reflecting a phase of reinvestment. Key concall takeaways from Credo Brands…

  • Entero Healthcare Solutions Ltd (Q1 FY27)

    Profit after tax (PAT) saw substantial growth in Q1, with a PAT margin of 2.7%; the company is focused on sustaining and building on this margin. Key concall…

  • Aditya Bir. Fas. (Q1 FY27)

    10% space addition). Key concall takeaways from Aditya Birla Fashion & Retail Ltd's Q1 FY27 earnings call — and how it ranks against sector peers.

Compare:vs Eternal Ltdvs Avenue Supermarts Ltdvs Trent

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →